Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma

Anti-Cancer Drugs

Volumn 19, Issue 2, 2008, Pages 201-207

  Recchia, Francesco ^a,b,e   Candeloro, Giampiero ^a   Necozione, Stefano ^c   Fumagalli, Luca ^d   Bratta, Massimo ^b   Rea, Silvio ^b,c  

^a Civilian Hospital   (Italy)

^b Foundation 'Carlo Ferri'   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e NONE   (Italy)

Author keywords

13 cis retinoic acid; Cisplatin; Dacarbazine; Interleukin 2; Metastatic melanoma; Pegylated a interferon; Vinblastine

Indexed keywords

CISPLATIN; DACARBAZINE; DEXAMETHASONE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; ISOTRETINOIN; PEGINTERFERON ALPHA2B; SEROTONIN 3 ANTAGONIST; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BEDTIME DOSAGE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; IMMUNOTHERAPY; LIVER TOXICITY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; DEXAMETHASONE; DIARRHEA; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2A; INTERLEUKIN-2; ISOTRETINOIN; MAGNESIUM SULFATE; MALE; MELANOMA; MIDDLE AGED; NEUTROPENIA; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE;

EID: 37849018470     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f2c0bc     Document Type: Article

References (40)

1. Eggermont AMM. Reaching first base in the treatment of metastatic melanoma. J Clin Oncol 2006; 29:4673-4674.
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
3. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-2052.
4. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:3477-3482.
5. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372-8377.
6. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumorinduced tolerance in metastatic melanoma. Int J Cancer 1997; 73:309-316.
7. Meidenbauer N, Zippelius A, Pittet MJ, Laumer M, Vogl S, Heymann J, et al. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 2004; 64:6319-6326.
8. Smith KA. Interleukin-2. inception, impact and implications. Science 1988; 240:1169-1176.
9. Thomas R, Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665-674.
10. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-562.
11. Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999; 22:145-154.
12. Dummer R, Garbe C, Thompson JA, Eggermont AM, Yoo K, Maier T, et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24:1188-1194.
13. Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett 1991; 57:223-227.
14. Bearzatto A, Orlandi L, Silvestrini R, Belli F, Cascinelli N, Zaffaroni N. Combined effects of interferon-alpha2a and 13-cis-retinoic acid on human melanoma cell growth and STAT protein expression. Melanoma Res 1998; 8:31-38.
15. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-1131.
16. Hengesbach L, Hoag K. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr 2004; 134:2653-2659.
17. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63:4441-4449.
18. Recchia F, de Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, et al. Phase IB study of subcutaneously administered interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res 2001; 7:1251-1257.
19. Recchia F, Saggio G, Amiconi G, di Blasio A, Cesta A, Ca ndeloro G, et al. Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma. J Immunother 2007; 30:448-454.
20. Recchia F, Saggio G, Nuzzo A, Biondi E, Blasio A, Cesta A, et al. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer. J Immunother 2006; 29:87-94.
21. Recchia F, Saggio G, Cesta A, Candeloro G, Nuzzo A, Lombardo M, et al. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. Int J Oncol 2005; 27:1039-1046.
22. Recchia F, Saggio G, Cesta A, Candeloro G, di Blasio A, Amiconi G, et al. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunol Immunother 2007; 56:699-708.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-481.
25. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
26. Mastrangelo MJ, Berd D, Bellet RE. Aggressive chemotherapy for melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology: updates. Vol. 5. Philadelphia: Lippincott; 1991. pp. 1-11.
27. Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF, Schaid DJ. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989; 63:224-227.
28. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.1. JAMA 1994; 271:907-913.
29. Atkins MB, Gollob JA, Sosman JA, Dermott DF, Tutin L, Sorokin P, et al. A phase II pilot trial of concurrent biochemotherapy cisplatin, vinblastine, temozolomide, interleukin IFN-α2B in patients with metastatic melanoma. Clin Cancer Res 2002; 8:3075-3081.
30. Atkins MB, Lee S, Flhaerty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003; 22:(abstr 2847).
31. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 2006; 106:1353-1357.
32. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006; 106:2437-2444.
33. Wolchok JD, Motzer RJ. Management of renal cell carcinoma. Oncology 2000; 14:29-35.
34. Triozzi PL, Walker MJ, Pellegrini AE, Dayton MA. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest 1996; 14:293-298.
35. Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. Am J Clin Oncol 1998; 21:352-354.
36. Sondak VK, Liu PY, Flaherty LE, Fletcher WS, Periman P, Gandara DR, et al. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. Cancer J Sci Am 1999; 5:41-47.
37. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group Trials. J Clin Oncol 2000; 18:3782-3793.
38. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994; 153:421-428.
39. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-1177.
40. Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLAA(*) 02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003; 104:437-445.